• Biote posted Q1 revenue of USD 44.9 million, down 8.3%, while net income fell to USD 2.7 million from USD 15.8 million a year earlier.
• Adjusted EBITDA slipped to USD 8.7 million from USD 13.8 million.
• Product revenue declined to USD 43.9 million from USD 47 million, while service revenue dropped to USD 1 million from USD 2 million.
• Asteria Health initiated a voluntary recall on Jan. 26 covering certain hormone pellet lots shipped between May 20, 2025 and Jan. 20, 2026; Biote estimated a USD 1.7 million hit to pellet-procedure revenue growth, recorded USD 1.5 million of recall-related costs, and expects additional costs.
• Cash and cash equivalents were USD 5.3 million at March 31, 2026, down from USD 24.1 million at Dec. 31, 2025; Biote said it expects existing liquidity and revolving capacity to fund operations and debt service for at least the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. biote Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-216780), on May 11, 2026, and is solely responsible for the information contained therein.